Comprehensive comparison of Zepbound and Mounjaro, two leading GLP-1 and GIP/GLP-1 medications for weight management.
Gila helps you build lasting habits, understand your body, and stay on track. Join the pilot for free.
Join the Pilot💡 **Know Your Meds:** Drugs.com published a fantastic comparison of Zepbound and Mounjaro! This deep dive is crucial for understanding the nuances of these powerful tools, whether you're already on one or exploring which might be the best fit for your unique journey. Knowledge is power, team!
Food noise is the constant, intrusive mental chatter about food that millions experience daily. This deep dive explains the neuroscience of how GLP-1 medications like semaglutide and tirzepatide quiet food noise by modulating the hypothalamus and reward pathways, distinguishes food noise from physiological hunger, and provides three evidence-based strategies — trigger-food visibility friction, small-plate pacing, and anchor meal templates — for managing it. Backed by research from JAMA, Cleveland Clinic, and NHS guidance.
Read more →
A JAMA Network Open study of 125,474 adults found that 53.6% discontinue GLP-1 medications within one year. This evidence-based analysis examines the six key reasons — side effects, cost, supply shortages, unrealistic expectations, premature cessation, and lack of support structure — and provides clinically-grounded strategies for staying on track, including the Weekly Plateau Scoreboard, Rebound Early-Warning Threshold, and structured side effect management. Anchored by STEP 4 trial data showing 14.8 percentage points difference between continuing and stopping.
Read more →Three oral GLP-1s now have FDA approval: Wegovy pill ($675/mo, Dec 2025), Foundayo orforglipron ($149/mo, April 2026), and Rybelsus (off-label). Trial data shows oral matches injection efficacy within 1-3pp. Here is the full comparison: efficacy, dose timing, side effects, cost.
Read more →